Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

  1. Motzer, R.J.
  2. Russo, P.
  3. Grünwald, V.
  4. Tomita, Y.
  5. Zurawski, B.
  6. Parikh, O.
  7. Buti, S.
  8. Barthélémy, P.
  9. Goh, J.C.
  10. Ye, D.
  11. Lingua, A.
  12. Lattouf, J.-B.
  13. Albigès, L.
  14. George, S.
  15. Shuch, B.
  16. Sosman, J.
  17. Staehler, M.
  18. Vázquez Estévez, S.
  19. Simsek, B.
  20. Spiridigliozzi, J.
  21. Chudnovsky, A.
  22. Bex, A.
Journal:
The Lancet

ISSN: 1474-547X 0140-6736

Year of publication: 2023

Volume: 401

Issue: 10379

Pages: 821-832

Type: Article

DOI: 10.1016/S0140-6736(22)02574-0 GOOGLE SCHOLAR